RCKT Rocket Pharmaceuticals
- 21.720
- -0.720-3.21%
Rocket Pharmaceuticals News
Buy Rating on Rocket Pharmaceuticals Amidst Positive Outlook and Strategic Execution
UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating
Rocket Pharmaceuticals (RCKT) has an average rating of Buy and price targets ranging from $39 to $65, according to analysts polled by Capital IQ. Price: 23.08, Change: -0.25, Percent Change: -1.07
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise
Rocket Pharmaceuticals (RCKT) said Friday that longer-term data on its experimental gene therapies to treat patients with rare blood disorders showed sustained safety and efficacy. Kresladi, a treatme
Rocket Pharmaceuticals Presents Positive Data From LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Long-term KRESLADITM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Optimistic Outlook for Rocket Pharmaceuticals With Advancing Pipeline and Solid Financials
10-Q: Quarterly report
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT)
Buy Rating Affirmed for Rocket Pharmaceuticals Amidst Promising Drug Approvals and Strong Financials
Rocket Pharmaceuticals (RCKT) Receives a Buy From William Blair
Rocket Pharmaceuticals Q1 EPS $(0.66) Beats $(0.69) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.69) by 4.35 percent. This is a 9.59 percent increase over losses of
Rocket Pharmaceuticals Sees Cash, Cash Equivalents and Investments of $330.3M Sufficient to Fund Ops Into 2026 >RCKT
Rocket Pharmaceuticals Sees Cash, Cash Equivalents and Investments of $330.3M Sufficient to Fund Ops Into 2026 >RCKT
Press Release: Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA
Rocket Pharmaceuticals 1Q Loss/Shr 66c >RCKT
Rocket Pharmaceuticals 1Q Loss/Shr 66c >RCKT
Insiders At Rocket Pharmaceuticals Sold US$2.0m In Stock, Alluding To Potential Weakness
The fact that multiple Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyz
Rocket Pharmaceuticals(RCKT.US) Director Sells US$1.95 Million in Common Stock
$Rocket Pharmaceuticals(RCKT.US)$ Director SOUTHWELL DAVID P sold 80,000 shares of common stock on Apr 12, 15, 2024 at an average price of $24.322 for a total value of $1.95 million.Source: Announceme
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing
David P Southwell, Director, on April 12, 2024, sold 80,000 shares in Rocket Pharmaceuticals (RCKT) for $1,945,785. Following the Form 4 filing with the SEC, Southwell has control over a total of 114,
Form 144 | Rocket Pharmaceuticals(RCKT.US) Director Proposes to Sell 240.52K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Rocket Pharmaceuticals(RCKT.US)$、$ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)(RCKTW.US)$ Director SOUTHWELL DAVID P intends to sell 10,000 shares of its c
Form 144 | Rocket Pharmaceuticals(RCKT.US) Director Proposes to Sell 1.71 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 12, $Rocket Pharmaceuticals(RCKT.US)$、$ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)(RCKTW.US)$ Director SOUTHWELL DAVID P intends to sell 70,000 shares of its c
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing
Mark Andrew White, General Manager, Commercial Affairs, on April 08, 2024, sold 12,532 shares in Rocket Pharmaceuticals (RCKT) for $308,763. Following the Form 4 filing with the SEC, White has control
Analysis
Price Target
No Data
